Patent application title: Recombinant allergen
Inventors:
Hans Grönlund (Lidingo, SE)
Hans Grönlund (Lidingo, SE)
Marianne Van Hage (Bromma, SE)
Assignees:
ImVisioN GmbH
IPC8 Class: AA61K3935FI
USPC Class:
4241851
Class name: Drug, bio-affecting and body treating compositions antigen, epitope, or other immunospecific immunoeffector (e.g., immunospecific vaccine, immunospecific stimulator of cell-mediated immunity, immunospecific tolerogen, immunospecific immunosuppressor, etc.) amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same
Publication date: 2009-05-07
Patent application number: 20090117136
cat (Felis domesticus) is one of the most common
causes of IgE mediated allergy. The present invention relates to a
recombinant folded Fel d 1 with molecular and biological properties
similar to the natural counterpart and specifically a synthetic gene
coding for a direct fusion of Fel d 1 chain 2 N-terminally to chain 1. E
coli expression resulted in a non-covalently associated homodimer with an
apparent molecular weight of 30 kDa defined by size exclusion
chromatography, each 19177 Da subunit displayed a disulfide pattern
identical to that found in the natural Fel d 1, and having identical fold
of natural and recombinant Fel d 1. The, recombinant Fel d 1 provides for
diagnosis and allergen specific immunotherapy of cat allergy.Claims:
1-21. (canceled)
22. A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2 and a linker selected from a carbon-nitrogen bond or a peptide linker having from 1 to 9 amino acid residues which links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain.
23. A fusion product as claimed in claim 22, wherein the linker links the N-terminal amino acid of the chain 1 to the C-terminal amino acid of the chain 2.
24. A fusion product as claimed in claim 22 or 23, wherein the linker is a carbon-nitrogen bond.
25. A fusion product as claimed in claim 22 or 23, wherein the short peptide has from 1 to 5 amino acid residues and preferably from 1 to 3 amino acid residues.
26. A fusion product as claimed in claim 22, wherein the linker comprises a target site for a reagent capable of selective cleavage of the linker.
27. A fusion product as claimed in claim 26, wherein the reagent is an enzyme.
28. A fusion product as claimed in claim 22, wherein the chain 1 and the chain 2 are covalently bonded together by one or more disulfide bridges into an antiparallel arrangement.
29. A fusion product as claimed in claim 22, wherein the Fel d 1 chain 1 comprises a sequence of SEQ ID NO 1, or a homologue or fragment thereof which provides substantially the same allergenic properties as SEQ ID NO 1.
30. A fusion product as claimed in claim 22, wherein the Fel d 1 chain 2 comprises a sequence of SEQ ID NO 2, SEQ ID NO 3, or a homologue or fragment thereof which provides substantially the same allergenic properties as SEQ ID NO 2 or SEQ ID NO 3.
31. A fusion product as claimed in claim 29 or 30, wherein the homologue has greater than 90% homology, preferably greater than 95% homology and particularly preferably greater than 99% homology.
32. A fusion product as claimed in claim 22, comprising a sequence of SEQ ID NO 4.
33. A homodimer consisting of two non-covalently associated fusion products as claimed in claim 22.
34. A DNA sequence encoding the fusion product as claimed in claim 22.
35. An expression vector having the DNA sequence as claimed in claim 34 inserted therein in an operable form.
36. A host cell transformed with the expression vector as claimed in claim 35.
37. A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.
38. A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.
39. A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33.
40. A process for preparing a fusion product as claimed in claim 22 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.
41. A process for preparing a recombinant Fel d 1 polypeptide comprising the steps of synthesising the fusion product as claimed in claims 26 or 27 and selectively cleaving the linker.Description:
[0001]This invention relates to a recombinant allergen and in particular
to a recombinant Fel d 1, the major cat allergen, which is functionally
equivalent to the natural allergen.
[0002]Exposure to airborne particles derived from household cats (Felis domesticus) is a common cause of IgE-mediated allergy in, for example, Europe and the US (see Ichikawa, K., et al. (1999) Clin Exp Allergy 29, 754-761; Roost, H. P., et al. (1999) J Allergy Clin Immunol 104, 941-947 and Lau, S., et al. (2000) Lancet 356, 1392-1397). Indeed, cats are found in about 25% of households in Western countries and allergy to cats is found in a large part of the population, e.g. about 10% in the US. The severity of symptoms range from relatively mild rhinitis and conjunctivitis to potentially life-threatening asthmatic exacerbation.
[0003]Treatment of cat allergy by allergen injections is often employed but clinical results are variable since for cat allergy, only crude dander extract is available for treatment (see Lilja, G., et al. (1989) J Allergy Clin Immunol 83, 37-44 and Hedlin, G., et al. (1991) J Allergy Clin Immunol 87, 95.5-964) although alternative formulations have been proposed (see Norman, P. S., et al. (1996) Am J Respir Crit Care Med 154, 1623-1628 and Oldfield, W. L., et al. (2002) Lancet 360, 47-53).
[0004]Although patients are occasionally sensitised to several different molecules in cat dander and pelts, e.g. albumin and cystatin, the major allergen is Fel d 1 (i.e. Felis domesticus allergen 1, formerly termed Cat 1). The importance of this allergen has been emphasised in numerous studies. In fact more than 80% of cat allergic patients exhibit IgE antibodies to this potent allergen (see Ohman, J. L., Jr., et al. (1977) J Allergy Clin Immunol 60, 317-323 and van Ree, R., et al. (1999) J Allergy Clin Immunol 104, 1223-1230).
[0005]Fel d 1, was first described 25 years ago as the dominant cat allergen and several subsequent studies have characterised the biochemical and immunological nature of Fel d 1 (see Ohman, J. L., Jr., et al. (1974) J Immunol 113, 1668-1677; Leitermann, K., et al. (1984) J Allergy Clin Immunol 74, 147-153; Chapman, M. D., et al. (1988) J Immunol 140, 812-818; Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309; Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694; van't Hof, W., et al. (1993) Allergy 48, 255-263; van Milligen, F. J et al. (1994) J Allergy Clin Immunol 93, 34-43; Vailes, L. D., et al. (1994) J Allergy Clin Immunol 93, 22-33; Counsell, C. M., et al. (1996) J Allergy Clin Immunol 98, 884-894; Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908 and Batard, T., et al. (2000) J Allergy Clin Immunol 106, 669-676).
[0006]The allergen is a 35-39 kDa acidic glycoprotein containing 10-20% N-linked carbohydrates and is found in the pelt, saliva and lachrymal glands of cats. It is formed by two non-covalently linked heterodimers, each consisting of one 70 residue peptide (known as "chain 1") and one 85, 90 or 92 residue peptide (known as "chain 2") encoded by separate genes (see Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309; Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908; Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694 and Griffith, I. J., et al. (1992) Gene 113, 263-268). (Chain 1 shares limited (30%) sequence homology with rabbit uteroglobulin/human Clara cell 10 kDa protein (CC10) and the mature natural (n)Fel d 1 has been associated with gelatin and fibronectin degrading activity.)
[0007]Several variants of Fel d 1 have been observed and are reported in the references cited hereinabove. The primary structure of chain 1 is the sequence of SEQ ID NO 1. Reported variants of chain 1 are Lys29→Arg or Asn and Val33→Ser. The primary structure of chain 2 is the sequence of SEQ ID NO 2 or 3. Reported variants of chain 2 are Asn19→Ser, Gly20→Leu, Ile55→Val, Arg57→Lys, Val58→Phe, Glu69→Val, Tyr72→Asp, Gln79→Glu and Asn88→Lys (see Kristensen, A. K, et al. (1997) Biol Chem 378, 899-908).
[0008]Furthermore, three inter-chain disulfide bridges linking the two peptides in native Fel d 1 have been identified, i.e. 3Cys(1)-73Cys(2), 44Cys(1)-48Cys(2) and 70Cys(1)-7Cys(2), suggesting an anti-parallel orientation of Fel d 1 peptides. See Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908.
[0009]Several attempts have been made to associate the separate peptides into a native-like allergen in E coli with only partial success (see Bond, J. F., et al. (1993) Mol Immunol 30, 1529-1541; Keating, K. M., et al. (1995) Mol Immunol 32, 287-293 and Slunt, J. B., et al. (1995) J Allergy Clin Immunol 95, 1221-1228) and recently a soluble and immunoreactive chain 1-linker-chain 2-fusion expressed in baculovirus has been described in which the linker is a peptide having 19 amino acid residues.
[0010]A mix of the separate chains has proven to be useful for in vitro allergy diagnosis, but so far no soluble, stable and correctly folded recombinant (r)Fel d 1 homodimer with retained disulfide formation has been available (see van Ree, R., et al. (1999) J Allergy Clin Immunol 104, 1223-1230 and Slunt, J. B., et al. (1995) J Allergy Clin Immunol 95, 1221-1228).
[0011]Accordingly, the present invention provides a recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2 and a linker selected from a carbon-nitrogen bond or a short-peptide linker which links the N-terminal amino, acid of one chain to the C-terminal amino acid of the other chain.
[0012]The present invention will now be described with reference to the following drawings, in which
[0013]FIG. 1 shows the primary structure and disulfide bridges of the recombinant His-tagged rFel d 1(2+1) fusion molecule;
[0014]FIG. 2 shows the results of size exclusion chromatography of rFel d 1(2+1);
[0015]FIG. 3 shows the deconvoluted electrospray mass spectrum from analysis of rFel d 1(2+1);
[0016]FIG. 4 shows the electrospray mass spectrum from analysis of non-reduced rFel d 1(2+1) digested with trypsin;
[0017]FIG. 5 shows the time-dependent dissociation analysis of immobilised rFel d 1(2+1) by surface plasmon resonance;
[0018]FIG. 6 shows the result of a far-UV CD analysis of rFel d 1 and nFel d 1;
[0019]FIG. 7 shows the IgE responses to Fel d 1 in individuals sensitised to cats in direct ELISA;
[0020]FIG. 8 shows the dose-dependent inhibition of serum IgE from a pool of individuals sensitised to cats; and
[0021]FIG. 9 shows the biologic activity of rFel d 1(2+1) and nFel d 1 in two patients allergic to cats.
[0022]The present invention demonstrates that a protein derived from a fusion of the genes coding for the two polypeptide chains constituting Fel d 1 can be folded to resemble closely the structure and allergenic activity of natural (n)Fel d 1. Surprisingly, it has been found that such a recombinant protein mimics the structure and allergenic activity of nFel d 1 when the two peptide chains are linked by a carbon-nitrogen bond or a short peptide linker. Synthetic genes coding for the two Fel d 1 chains may be produced using known techniques, for example by PCR by overlapping oligonucleotides and expression as refolded His-tagged proteins in E coli. Two possible constructs, namely one with chain 1 and the other with chain 2 in the N-terminal position, are exemplified. Both constructs have been purified to homogeneity and analysed, in particular for intra-molecular disulfide bridges and homodimer formation using techniques such as size exclusion chromatography, mass spectrometry and surface plasmon resonance.
[0023]As explained hereinabove, the two polypeptide chains constituting nFel d 1 are known and described extensively in the prior art. The sequence of chain 1 of nFel d 1 is as shown in SEQ ID NO 1 and the sequence of chain 2 is as shown in SEQ ID NO 2 or 3. However, as well as the variants described hereinabove, any homologous peptide or peptide fragment which has substantially the same sequence and/or provides substantially the same function in the rFel d 1 as chain 1 or chain 2 of nFel d 1 may be used in the present invention. The homologues or fragments of chain 1 or chain 2 must provide substantially the same allergenic activity in the rFel d 1 of the present invention as in nFel d 1. Allergenic activity may be measured by any of the known techniques in the art, such as the response to IgE. Preferably no significant difference in response to IgE between the recombinant and natural Fel d 1 is observed. Preferably the homologues should also provide for the adoption of substantially the same conformation as in nFel d 1.
[0024]The linker which links chain 1 and chain 2 is a key feature of the present invention. Although attempts have been made to provide a rFel d 1 using chains 1 and 2 from nFel d 1 with a linker, such efforts have been unsuccessful. The present applicant has found, however, that rFel d 1 which mimics the properties of nFel d 1 may be obtained by linking chain 1 and chain 2 with a linker selected from a carbon-nitrogen bond and a short peptide, i.e. having from 1 to 9, preferably 1 to 5, particularly preferably 1 to 3 amino acids.
[0025]Surprisingly, a bond or a short peptide does not induce significant constraints or unfolding, as shown by comparison with nFel d 1 in circular dichroism (CD) measurements.
[0026]Preferably the linker is a carbon-nitrogen bond thereby providing a direct fusion between chain 1 and chain 2. An advantage of direct fusion is that no extra amino acids are included within the molecule which otherwise might compromise the use of the molecule in diagnosis and treatment. However, a short (1 to 9 amino acids) peptide bond may be tolerated. An advantage of including a short peptide chain is that the linker may then be used as a target site for a reagent, such as an enzyme, capable of selectively cleaving the polypeptide at the linker. By selective, the applicant means that the polypeptide is cleaved at the linker rather than within chain 1 or chain 2. Such a cleavage would then provide a rFel d 1 having substantially the same structure as nFel d 1, i.e. in which chain 1 and chain 2 are covalently bonded together only by the disulfide bridges.
[0027]The present invention therefore also provides a process for preparing a recombinant Fel d 1 peptide comprising the steps of synthesising the peptide having the linker as described herein and selectively cleaving the polypeptide at the linker, using a suitable reagent and preferably an enzyme. Such reagents and enzymes are well known in the art.
[0028]The linker links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain. Preferably the linker links the N-terminal amino acid of chain 1 to the C-terminal amino acid of chain 2 providing a so-called (2+1) construct. Thus, rFel d 1(1+2) contains chain 1 and chain 2 in which the C-terminal of chain 1 is fused to the N-terminal of chain 2 and rFel d 1(2+1) contains chain 1 and chain 2 in which the N-terminal of chain 1 is fused to the C-terminal of chain 2 as shown in FIG. 1 and SEQ ID NO 4. Both chains show specific IgE reactivity although results suggest that rFel d 1(2+1) exhibits superior IgE reactivity to rFel d 1(1+2).
[0029]As well as the linker described hereinabove, chains 1 and 2 of the rFel d 1 of the present invention will also be linked by one or more disulfide bridges on account of the presence of cysteine residues in each chain. Biological recognition of proteins is dependent on the primary structures, displayed as linear T cell epitopes in the cavity of MHC molecules on antigen presenting cells. Equally important for the biological functions are the three-dimensional structures, which in turn depends on secondary structure and frequently on correct and stable disulfide bridges. The rFel d 1 should have at least one disulfide bridge and preferably 2 or 3, particularly preferably 3, as in nFel d 1. The applicant has analysed rFel d 1(2+1) by CD measurements and determined the intra-chain disulfide linking through trypsin cleavage and mass spectrometry. The secondary structure and disulfide bridges pattern of nFel d 1 as well as the proliferation of cultured PBMC in the presence of nFel d 1 were found to correspond well to those observed for rFel d 1(2+1). Thus, the rFel d 1 forms a basis for a stable and immunoreactive allergen
[0030]An important structural feature of nFel d 1 is the formation of stable non-covalently associated homodimers. The ability of rFel d 1(2+1) to form homodimers has been investigated by several methods, including CD spectroscopy and analysis of IgE antibody responses in direct and competition ELISA using sera from individuals sensitised to cat was carried out. The biological activity was demonstrated by the induction of CD203c on basophils of cat allergic patients.
[0031]The 30 kDa rFel d 1(2+1) fraction isolated by size exclusion chromatography (SEC) indicates a homodimer by virtue of its elution position and corresponding molecular weight. The difference in molecular weight to the cat dander derived 35-38 kDa nFel d 1 may be explained by the presence of 10-20% N-linked carbohydrates in the natural allergen. The applicant further investigated the possible homodimer formation via re-chromatography of the isolated 30 kDa fraction by SEC under dissociating conditions. Now the corresponding component eluted as a 15 kDa peak in agreement with the findings from SDS-PAGE using non-reduced sample, suggesting a non-covalently associated dimer. Finally, the rFel d 1(2+1) was analysed by surface plasmon resonance with the assumption that a dissociation rate should be possible to calculate if a dimer was attached to the chip. The time-dependent dissociation indicated a tight protein-protein association which was also supported by the fact that no peak corresponding to the size of a monomer could be detected in SEC. Furthermore, the sensorgram obtained suggested a dimer by the roughly 50% decrease in response measured after deactivation.
[0032]From a clinical perspective, as well as for epitope probing, it is important to establish accurate levels of allergen-specific antibodies in serum from e.g. cat-allergic patients. The ability to detect allergen specific IgE in serum from 15 cat-allergic patients to rFel d 1(2+1), nFel d 1 and a mixture of Fel d 1 peptides, was evaluated using direct ELISA. No significant difference in response to IgE was detected for recombinant and natural Fel d 1 indicating that all relevant IgE epitopes are present in the rFel d 1(2+1) structure. Also, the results confirm that the carbohydrate side-chain is not crucial for the folding or else serves as an epitope of nFel d 1. The comparable behaviour of rFel d 1 and nFel d 1 was also implied in the competition ELISA.
[0033]rFel d 1 and nFel d 1 revealed the same capacity to compete with IgE in serum for binding to microtitre plate bound nFel d 1 in ELISA. The somewhat better homologous inhibition achieved using high concentrations of nFel d 1 is likely to be caused by the inhibition of antibodies present in the serum pool by matching impurities in the nFel d 1 preparation. A mixture of chains 1 and 2 (with no linker) showed significantly lower IgE binding capacity in direct ELISA and a lower specific activity in the inhibition assay, suggesting a distorted protein preparation with fewer exposed epitopes.
[0034]The present invention also provides a DNA sequence encoding the rFel d 1 described herein as well as an expression vector capable of expressing the DNA sequence in an operable form. Although exemplified by E. coli, the skilled person would be aware that other known cell lines would be capable of preparing rFel d 1. Accordingly the present invention also provides a host cell transformed with the expression vector as described above. A high level expression E coli system which produces proteins without the attached carbohydrates has been exemplified herein. However, other known systems may be used which provide for the attached carbohydrates and fall within the scope of the present invention.
[0035]rFel d 1 of the present invention may be used for diagnosis and therapy of cat-allergic patients. Specifically the present invention provides a pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product and/or the homodimer as described herein. The present invention also provides for the use of the fusion product and/or the homodimer as described herein for the preparation of a medicament for the treatment or prevention of cat allergy as well as a method for treating cat allergy, using the fusion product and/or the homodimer as described herein.
[0036]The present invention also provides a kit for the diagnosis of a cat allergy comprising the fusion product and/or the homodimer as described herein as well as a method for the diagnosis of an cat allergy comprising obtaining a sample from a subject and combining with the sample the fusion product and/or the homodimer as described herein.
[0037]Although the subject treated or diagnosed is preferably a human subject, the subject may be any non-human mammal, such a dog.
EXAMPLES
Example 1
Natural and Recombinant Fel d 1
[0038]Standard (see Ausubel, F. A., et al. (eds) (1998) Current Protocols in Molecular Biology, John Wiley & Sons, New York) or manufacturers' protocols were used for DNA manipulations. From published amino acid sequences of Fel d 1 chain 1 and 2 (see Chapman, M. D., et al. (1988) J Immunol 140, 812-818; Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309 and Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694) synthetic genes were made by PCR-amplification (Eppendorf Mastercycler, Hamburg, Germany) using overlapping DNA-primers from DNA Technology A/S (Århus, Denmark) as shown in Table 1 and which are designated as SEQ ID NOS 5-15. In Table 1, restriction enzyme sites (Nde I and Xho I) are underlined. Forward (F) and reverse (R) primers are indicated.
TABLE-US-00001 TABLE 1 Primer no. Sequence 1(F) 5'-gtacatatg g aaatctgccc ggctgttaaa cgtgacgttg acctgttcct gaccggtacc ccggacgaat acgttgaaca ggttg-3' 2(R) 5'-ggcagagctt tgtactgagc aacctgttca acgtattcgt ccgggtgagc aacctgttca acgtattc-3' 3(F) 5'-tgctcagtac aaagctctgc cggttgttct ggaaaacgct cgtatcctga aaaactgcgt tgacgctaaa atgacc-3' 4(R) 5'-cctctcgag g cacagcgggg aggtgtagat tttgtccagc agggacagag cgttttcttt gtcttcttcg gtcattttag cgtcaacgc-3' 5(F) 5'-gtacatatg g ttaaaatggc tgaaacctgc ccgatcttct acgacgtttt cttcgctgtt gctaacggta acgaac-3' 6(R) 5'-ggtacgttcc ggttcggtag cgttaacttt ggtcagggac aggtccagca gcagttcgtt accgttagca acagc-3' 7(F) 5'-ctaccgaacc ggaacgtacc gctatgaaaa aaatccagga ctgctacgtt gaaaacggtc tgatctcccg tgttctggac-3' 8(R) 5'-gcttcaccca tgcagtcttt ggaggaggag atggtggtca taaccagacc gtccagaaca cgggagatca g-3' 9(F) 5'-caaagactgc atgggtgaag ctgttcagaa caccgttgaa gacctgaaac tgaacaccct gggtcgctcg agagg-3' 10(R) 5'-cctctcgag a cgacccaggg tg-3' 11(linker) 5'-cgtttaacag ccgggcagat ttcacgaccc agggtgttca gtttc-3'
[0039]PCR-reactions (10 μl) containing 1 pmol of each primer, 1-4 for chain 1 and 5-10 for chain 2, using AmpliTaq DNA polymerase (Applied Biosystems, Foster City, Calif., USA) was used. The reactions proceeded for 1.0 min at 94° C., 1.5 min at 65° C. and 2.0 min at 68° C. for 30 cycles. The PCR products were ligated into pT7Blue Blunt Vector, transformed into Nova Blue Single Competent cells using Perfectly Blunt Cloning Kit Novagen Inc., Madison, Wis., USA). Single colonies were grown in 2.5 ml LB medium containing 100 μg/ml ampicillin and plasmids were purified (Qiagen, GmbH, Hilden, Germany) and cut with the restriction enzymes Nde I and Xho I followed by electrophoretic analysis in 0.3 μg/ml ethidium bromide in 1% agarose gels. Clones with the right size insert (210 and 276 bp for chain 1 and 2, respectively) were sequenced (ABI PRISM® 377 DNA Sequencer, Applied Biosystems). Verified plasmids were used as templates to join chains 2 and 1, using primers 4, 5 and 11 as described for the single chains. After sequencing, the fusion constructs were subcloned into pET 20b (Novagen) using the Nde I/Xho I restriction sites and transformed into E coli strain BL-21(DE3)pLysS (Novagen). Clones were selected on LB agar plates with ampicillin (100 mg/l) and chloramphenicol (30 mg/l) and grown in LB medium containing 100 μg/ml ampicillin and 30 μg/ml chloramphenicol. pET 20b inserts of chain 1, chain 2 and rFel d 1(2+1) were sequence verified, (ABI). Expression of protein was induced for 3 h in midlog-phase using 0.4 mM isopropyl-thiogalactoside. The cells were pelleted using a J2-21 centrifuge (Beckman Instruments Inc., Palo Alto, Calif., USA) at 1000×g for 10 min and stored at -20° C. Natural Fel d 1 (>90% pure) from Indoor Biotechnologies (Charlottesville, Va., USA) was used for comparison of immunoreactivity and biological activity between samples.
Example 2
Purification and Characterisation of Recombinant Fel d 1
[0040]Protein purification was performed using FPLC, (Amersham Biosciences, Uppsala, Sweden). The same purification protocol was used for all recombinant constructs. The E coli pellets containing the expressed recombinant construct were resuspended in 20 mM Tris/HCl, 0.2 M NaCl, 1 mM EDTA, pH 7.4, and disrupted via 8×10 seconds sonication bursts on ice (Soniprep 150 Ultrasonic Disintegrator, Sanyo Gallenkamp, Uxbridge, UK) followed by centrifugation at 12000×g for 25 min (Beckman Instruments). This procedure was repeated twice, after which the pelleted inclusion body preparation was solubilised in 6 M guanidine/HCl, 20 mM Tris/HCl, 0.5 M NaCl, 5 mM imidazole, pH 8.0, and loaded onto a 5 ml Ni+-HiTrap affinity column (Amersham Biosciences) operated at 5 ml/min. The column buffer was changed to 6 M urea, 20 mM Tris/HCl, 0.5 M NaCl, 20 mM imidazole, pH 8.0, and a linear gradient was formed to reach 20 mM Tris/HCl, 0.5 M NaCl 20 mM imidazole, pH 8.0, after 12 column volumes. The protein was eluted with 20 mM Tris/HCl, 0.5 M NaCl, 0.5 M imidazole, pH 8.0. The enriched rFel d 1 preparation was purified by size exclusion chromatography (SEC) (HiLoad® 16/60 Superdex 200 pg, Amersham Biosciences) equilibrated in PBS and in PBS with 0.1% SDS at 1 ml/min. Molecular weight calibration of the column was carried out using bovine serum albumin (BSA), 67 kDa; ovalbumin, 43 kDa; chymotrypsinogen A, 25 kDa and ribonuclease A, 13.7 kDa (Amersham Biosciences) dissolved in PBS or PBS with 0-1% SDS. The relative elution of reference proteins and rFel d 1(2+1) was calculated according to the formula Kav=Ve-VoNt-Vo (see Scopes, R. K. (1994) Protein Purification, Principles and Practice, 3rd ed. Ed (Cantor, C. R., Ed.), Springer-Verlag, New York, USA). Purified proteins were stored at -80° C. until use.
[0041]The protein concentration of rFel d 1(2+1) was analysed by amino acid analysis using a Biochrom 20 Plus ninhydrin-based analyser (Amersham Biosciences) after hydrolysis at 110° C. for 24 h in evacuated tubes with 6 M HCl containing 0.5% (w/v) phenol. The BCA protein assay (Pierce, Rockford, Ill., USA) was sometimes used to estimate the protein concentration. Purity was judged by SDS-PAGE using 15% homogeneous gels and low molecular weight markers (Amersham Biosciences). Samples were denatured at 98° C. for 5 min in SDS sample buffer with or without β-mercaptoethanol (see Ausubel, F. A., et al. (eds). (1998) Current Protocols in Molecular Biology, John Wiley & Sons, New York).
Example 3
Electrospray Mass Spectrometry and Determination of Disulfide Bridges
[0042]For mass determination of rFel d 1(2+1), the folded protein was dissolved at 27 pmol/μl in 10 mM ammonium acetate (pH 7.3) and was applied to electrospray ionisation (ESI) mass spectrometry (below) via direct infusion using a syringe pump at 2-5 μl/min (Harvard Apparatus, Holliston, Mass., USA).
[0043]To localise disulfide bridges, 2.7 mmol of the folded rFel d 1(2+1) was dissolved in 10 μl 9 M urea and incubated 30 min under vortex at 45° C. after which 10 μl water was added. Modified trypsin (5 μg, Promega) and 10 μl 0.5 M ammonium bicarbonate (pH 8.0) were added followed by water to yield a final volume of 100 μl. Digestion proceeded overnight under vortex at 37° C. The reaction was quenched by adding 1 μl neat trifluoroacetic acid to the sample which was stored at -20° C. until analysed. Before mass spectrometry, aliquots of the tryptic digest (10 μl) were desalted on μ-C18 ZipTips (Millipore, Bedford, Mass.; USA) and eluted in 60% acetonitrile containing 1% acetic acid for nano-ESI mass spectrometry. To make sure that no free sulfhydryl groups existed in rFel d 1(2+1), alkylation was carried out on the non-reduced recombinant preparation (5.4 nmol) using iodoacetamide (Sigma, St. Louis, Mo., USA) at 5.5 mM in 20 mM ammonium bicarbonate (pH 8.0) for 15 min at room temperature followed by desalting on μ-C4 ZipTips and nano-ESI mass spectrometry.
[0044]Mass spectra were recorded using a quadrupole time-of-flight tandem mass spectrometer, Q-TOF (Micromass, Altrincham, UK). The instrument was equipped with an orthogonal sampling ESI-interface (Z-spray, Micromass). Metal-coated nano-ESI needles (Protana, Odense, Denmark) were used and manually opened on the stage of a light microscope to give a spraying orifice of about 5 μm. This resulted in a flow of approximately 20-50 nL/min when a capillary voltage of 0.8-1.2 kV was applied. A nitrogen counter-current drying gas facilitated desolvation. The cone voltage was set at 40 V.
[0045]The amino acid sequence and the disulfide bridges as determined by nano-ESI mass spectrometry after tryptic digestion of the E coli expressed (His)6-tagged rFel d 1(2+1) fusion protein is shown in FIG. 1 and SEQ ID NO 4. Following column folding and purification by Ni+-chelate chromatography, dominant fractions in SEC with apparent molecular weights of 30 kDa and 51 kDa (FIG. 2) were recovered for further analysis. The 51 kDa component contained inter-chain S--S bonds as shown by a 35 kDa band in non-reducing and a 20 kDa band in reducing SDS-PAGE and was not further analysed (FIG. 2). The 30 kDa fraction which showed a single 30 kDa peak upon re-chromatography, exhibited 16 and 20 kDa bands by non-reducing and reducing SDS-PAGE respectively, (FIG. 2). When subjected to electrospray mass spectrometry, rFel d 1(2+1) revealed a molecular mass of 19177 Da, which corresponds to the average molecular mass (19183 Da) minus 6 Da, indicating the existence of three disulfide bridges in the structure (FIG. 3). Also seen is an additional peak at 19046 Da, which corresponds to the full-length rFel d 1 without the initiating methionine (Table 1, and residue 0 in FIG. 1 and SEQ ID NO 4). The purity of both the natural and recombinant preparations were >95% as judged by SDS-PAGE (data not shown).
[0046]The disulfide bridge formation in rFel d 1(2+1) was analysed by nano-ESI mass spectrometry after trypsin digestion of the non-reduced preparation and the results are shown in Table 2 and FIG. 4.
TABLE-US-00002 TABLE 2 Theoretial Experimental Tryptic mass mass fragment Residues Sequence [M + H] [M + H] T5 44-44 (K)K(I) 147.11 not found TI1 100-100 (K)R(D) 175.12 not found T14 132-134 (R)ILK(N) 373.28 not found TI 0-2 (-)MVK(M) 377.22 not found T4 40-43 (R)TAMK(K) 450.24 450.75 T9 87-92 (K)LNTLGR(E) 673.40 673.40 T16 141-146 (K)MTEEDK(E) 752.31 not founda T3 32-39 (K)VNATEPER(T) 915.45 915.44 T17 147-155 (K)ENALSLLDK(I) 1002.55 not founda T13 122-131 (K)ALPVVLENAR(I) 1081.64 1081/60 T7 58-71 (R)VLDGLVMTTISSSK(D) 1450.78 1450.72 T6 45-57 (K)IQDCYVENGLISR(V) 2156.01 2155.98 T15 135-140 (K)NCVDAK(M) T8 72-86 (K)DCMGEAVQNTVEDLK(L) 2408.11 2408.07 T10 93-99 (R)EICPAVK(R) T12 101-121 (R)DVDLFLTGTPDEYYEQVAQYK(A) 2430.17 2430.09 T2 3-31 (K)MAETCPIFYDVFFAVANGNELLLDLSLTK(V) 5092.46 5092.28 T18 156-170 (K)IYTSPLCLEHHHHHH(-) T16 + 17 141-155 (K)MTEEDKENALSLLDK(I) 1735.86 1735.80 a Not found as a separate fragment. Detected as a part of the larger fragment T16 + T17 with [M + H] 1735.80, resulting from a miscleavage at Lys146 which is surrounded by acidic residues, see FIG. 1.
Example 4
Homodimer Dissociation Constant Analysis
[0047]A BIACORE® 2000 instrument (Biacore AB, Uppsala, Sweden) was employed to investigate homodimer formation of rFel d 1(2+1) by evaluation of the decrease in response relative to maximum binding to the chip surface and the associated dissociation constant. rFel d 1(2+1) and for control purpose a monomer protein, BB (see Batard, T., et al. (2000) J Allergy Clin Immunol 106, 669-676), were immobilised onto the surface of CM-5 chips (research grade) via amine coupling to a carboxylated dextran layer using N-hydroxysuccinimide/N-ethyl-N'-(3-diethylaminopropyl)carbodiimide (NHS/EDC) chemistry according to the manufacturers recommendations. The time intervals between surface activation (240-660 s, 35 μl), protein immobilisation (900-1140 s, 20 μl) dissociation phase (1140-1940 s, 67 μl) and surface deactivation (1940-2060 s, 10 μl) were kept constant. In the immobilisation step, 20 μl of a protein solution containing 0.05 μg/μl in 10 mM sodium acetate (pH 4.5) was injected over the NHS/EDC activated surface. After the dissociation phase, the surface was deactivated by injection of 10 μl ethanolamine. The decrease in percent of protein initially attached to the chip surface was calculated as follows: [Response Units (RU) after protein immobilisation at 1230 s--RU after deactivation/RU after protein immobilisation]×100. All experiments were performed at 25° C. and 5 μl/min. The running buffer was 10 mM Hepes (pH 7.4), 0.15 M NaCl, 3.4 mM EDTA, 0.05% surfactant P20. The dissociation constant analysed at 1230-1235 s was based on the equilibrium responses and calculated using the 3.0 software.
[0048]The 30-40 kDa molecular size detected for rFel d 1(2+1) suggests a non-covalent dimerisation similar to that exhibited by natural Fel d 1. This was investigated by BIACORE® analysis and by SEC under dissociating elution conditions. In the latter case, the 30 kDa rFel d 1(2+1) fraction produced a single peak corresponding to a molecular weight of 15 kDa using PBS with 0.1% SDS in the running buffer (data not shown). The 30 kDa fraction was further analysed by surface plasmon resonance with the assumption that dissociation of the two subunits can be recorded. As a control, monomeric protein, BB (39), was used, (FIG. 5). The rFel d 1(2+1) construct and the BB monomer bound to the sensor chip in a similar manner. The time-dependent decrease in RU after immobilisation of the rFel d 1(2+1) molecule to the chip surface was 53%. In contrast, the BB monomer exhibited a stable association to the chip surface during the same time period. In addition, the dissociation constant was determined shortly after the immobilisation phase to be 8.74 10-4 s-1.
Example 5
CD Measurements
[0049]CD measurements of the natural and recombinant Fel d 1 were performed in MilliQ water with protein concentrations of 1.56×10-5 M (here determined using Bio-Rad Protein Assay, Bio-Rad Laboratories, Vienna, Austria). The investigations were carried out on a Jasco J-715 spectropolarimeter (JASCO Labor-und Datentechnik GmbH, Gross-Umstadt, Germany) using a 0.1 cm pathlength cell equilibrated at 20° C. Spectra were recorded with 0.5 nm resolution at a scan speed of 100 nm/min and resulted from averaging 3 scans. The final spectra were baseline-corrected by subtracting the corresponding MilliQ spectra obtained under identical conditions. Results were expressed as the molar mean residue ellipticity [Θ] at a given wavelength. The data were fitted with the secondary structure estimation programs Dicroprot (37) and J-700 (JASCO) using miscellaneous data deconvolution algorithms.
[0050]The 20° C. CD spectra of natural and recombinant Fel d 1 are nearly identical, characterised by two minima at 208 nm and 222 nm and a characteristic maximum at about 195 nm (FIG. 6). The shape of the spectrum is indicative for a well folded protein with a significant α-helical secondary structure content. The secondary structure estimation resulting from the fitting procedures yields 35-40% α-helix and 7-16% β-sheet structures with root mean square deviations (CD.sub.calc-CD.sub.exp) in the range 4-11%.
Example 6
ELISA Analysis
[0051]Serum specimens from 15 individuals were selected on the basis of positive IgE responses to cat dander (range 0.45-38 kUA/L using Pharmacia Diagnostics CAP System, Uppsala, Sweden). For control purpose, a pool of 20 non-cat-allergic patients was used. The serum samples were analysed in duplicates by ELISA for IgE antibody binding to rFel d 1(2+1), nFel d 1 or a mix of rFel d 1 chain 1 and chain 2. The assay was performed as a sequential, solid phase adsorption of allergens, serum sample, primary antibody, antibody conjugate and finally substrate including rinsing four times with 250 μl PBS containing 0.05% Tween 20 (PBS-T) between incubations. If nothing else is stated, all steps were performed at room temperature. Micro titre plates (96 wells, Nunc, Roskilde, Denmark) were coated with 100 μl of rFel d 1(2+1) solution and for comparison also nFel d 1 and an equimolar mixture of chains 1 and 2, to final concentrations of 5 μg/ml in 0.1 M carbonate buffer, pH 9.6. After over-night adsorption at +4° C., the plates were emptied and the remaining protein binding sites were blocked with 200 μl PBS-T containing 1% BSA for 2.5 h at room temperature (20-22° C.). Each serum sample (100 μl) was diluted 1:1 in PBS (duplicates) and incubated for 2 h at room temperature, after which 100 μl rabbit anti-human IgE (Miab, Uppsala, Sweden, diluted 1:2000 (v/v)) was added and incubation was continued for 2 h. Finally, 100 μl goat anti-rabbit, (Dako, Denmark, diluted 1:2000 (v/v)) conjugated to alkaline phosphatase was added and incubation continued for 1 h. Alkaline phosphatase substrate tablets (Sigma 104® Diagnostics, St Louis, Mo., USA) were used and the color reaction monitored at 405 nm was registered in an automated ELISA reader (Multiskan RC, Labsystems, Helsinki, Finland). Competition assay of serum IgE was performed using pooled sera from individuals sensitised to cat with more than 10 kUA/L response to cat dander (mean concentration, 23 kUs/L), (Pharmacia Diagnostics CAP System). Micro-titre plates (96 wells) were coated with 100 μl, 5 μg/ml nFel d 1. Three-fold serial dilutions in PBS-T of rFel d 1(2+1), nFel d 1 and an equimolar mixture of chain 1 and 2 were incubated at a 1:1 volume ratio with the serum pool diluted 1:2 (v/v) in PBS for 2 h at room temperature and thereafter added to the wells. The subsequent steps were as described for the direct ELISA.
[0052]The diagnostic relevance of a recombinant allergen lies in its ability to bind specifically IgE antibodies in body fluids or in tissues from allergic patients in a manner similar to the natural counterpart. This ability of IgE antibodies in sera from 15 subjects sensitised to cat was compared to detect rFel d 1(2+1), nFel d 1 and a Fel d 1 peptide mixture using ELISA. All sera from cat allergic patients showed elevated IgE concentrations compared to a pool of serum from non-cat allergic patients (FIG. 7). Similar responses for rFel d 1(2+1) (optical density (OD) mean, 0.412) and nFel d1 (OD mean, 0.384) were observed. There was a significantly lower IgE response to the peptide mixture (OD mean, 0.288) compared to rFel d 1(2+1) and nFel d 1, (ANOVA p<0.001 and p<0.01, respectively).
[0053]The capacity of serially diluted rFel d 1(2+1), nFel d 1 and a mixture of chain 1 and chain 2 to compete with the binding of patient IgE to microtitre plate bound nFel d 1 was compared using ELISA. All three Fel d 1 preparations exhibited competing activity. The rFel d 1(2+1) fusion protein inhibited IgE similar as nFel d 1, shown by the proximity and slopes of the dose-dependent inhibition curves in the sensitive range (0.01-0.33 μg/ml), (FIG. 8). The mixture of chain 1 and 2 exhibited more than a 25-fold reduced capacity to compete with IgE binding. By homologous inhibition of nFel d 1, a residual capacity to block IgE was evident using 1 and 3 μg/ml.
Example 7
CD203c Assay
[0054]The expression of CD203c was performed as described (see Hauswirth, A. W., et al. (2002) J Allergy Clin Immunol 110, 102-109). Briefly, heparinised blood samples were taken from two cat allergic patients. Blood aliquots (100 μl) were incubated with dilutions of recombinant and natural Fel d 1 (1 and 10 μg/ml), anti-IgE antibody (1 μg/ml) or PBS for 15 min (37° C.). After incubation, cells were washed in PBS/EDTA and then incubated with 10 μl of phycoerythrin-labeled CD203c mAb 97A6 (Immunotech, Marseille, France) for 15 min at room temperature. Thereafter, samples were subjected to erythrocyte lysis with 2 ml FACS® Lysing solution (Becton Dickinson, San Diego, Calif., USA). Cells were then washed, resuspended in PBS, and analysed by two-colour flow cytometry on a FACScan (Becton Dickinson).
[0055]The biological activity of rFel d 1(2+1) and nFel d 1 was evaluated in cell preparations donated by two cat allergic patients. The surface marker CD203c is upregulated exclusively on basophils in response to allergen cross-linking of the high affinity IgE receptor, FcεRI (38). The capacity of rFel d 1(2+1) and nFel d 1 to activate expression of CD203c on basophils was similar and compared well to that of anti-IgE, which was used as a positive control (FIG. 9a).
Example 8
Lymphoproliferation Assay
[0056]Peripheral blood mononuclear cells (PBMC) were isolated from cat-allergic patients by Ficoll (Amersham Biosciences) density gradient centrifugation. PBMC (2×105) were cultured in triplicates in 96-well Nunclone plates (Nunc) in 200 μl serum-free Ultra Culture medium (BioWhittaker, Rockland, Me.) supplemented with 2 mM L-glutamin (Sigma), 50 μM β-mercaptoethanol (Sigma) and 0.1 mg gentamicin per ml (Sigma) at 37° C. and 5% CO2 in a humidified atmosphere. Cells were stimulated with different concentrations (5, 2.5, 1.25 and 0.6 μg per well) of rFel d 1, nFel d 1 and for control purpose with recombinant birch pollen allergen Bet v 1, 4 U Interleukin-2 (IL-2) per well (Boehringer Mannheim, Germany) and medium alone. After 6 days of culture, 0.5 μCi per well [3H]thymidine (Amersham Biosciences) was added and 16 h thereafter incorporated radioactivity was measured by liquid scintillation counting using a Microbeta scintillation counter (Wallac ADL, Freiburg, Germany) and mean counts per minute (cpm) were calculated from the triplicates. The stimulation index (SI) was calculated as the quotient of the cpm obtained by antigen or interleukin-2 stimulation and the unstimulated control.
[0057]The lymphoproliferative responses after challenge of cultured PBMCs with rFel d 1(2+1) and nFel d 1 were analysed by cell incorporation of [3H]thymidine. Both rFel d 1(2+1) and nFel d 1 exhibited equally good proliferation in contrast to the major birch pollen allergen Bet v 1, which was used as a negative control (FIG. 9b). The T cell proliferation inducing growth factor IL-2 was used as a positive control.
Example 9
Statistical Analysis
[0058]Serological results using rFel d 1(2+1), nFel d 1 and the Fel d 1 peptide mixture in the direct ELISA were compared employing ANOVA repeated measures. A p-value <0.05 was considered statistically significant.
Claims:
1-21. (canceled)
22. A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2 and a linker selected from a carbon-nitrogen bond or a peptide linker having from 1 to 9 amino acid residues which links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain.
23. A fusion product as claimed in claim 22, wherein the linker links the N-terminal amino acid of the chain 1 to the C-terminal amino acid of the chain 2.
24. A fusion product as claimed in claim 22 or 23, wherein the linker is a carbon-nitrogen bond.
25. A fusion product as claimed in claim 22 or 23, wherein the short peptide has from 1 to 5 amino acid residues and preferably from 1 to 3 amino acid residues.
26. A fusion product as claimed in claim 22, wherein the linker comprises a target site for a reagent capable of selective cleavage of the linker.
27. A fusion product as claimed in claim 26, wherein the reagent is an enzyme.
28. A fusion product as claimed in claim 22, wherein the chain 1 and the chain 2 are covalently bonded together by one or more disulfide bridges into an antiparallel arrangement.
29. A fusion product as claimed in claim 22, wherein the Fel d 1 chain 1 comprises a sequence of SEQ ID NO 1, or a homologue or fragment thereof which provides substantially the same allergenic properties as SEQ ID NO 1.
30. A fusion product as claimed in claim 22, wherein the Fel d 1 chain 2 comprises a sequence of SEQ ID NO 2, SEQ ID NO 3, or a homologue or fragment thereof which provides substantially the same allergenic properties as SEQ ID NO 2 or SEQ ID NO 3.
31. A fusion product as claimed in claim 29 or 30, wherein the homologue has greater than 90% homology, preferably greater than 95% homology and particularly preferably greater than 99% homology.
32. A fusion product as claimed in claim 22, comprising a sequence of SEQ ID NO 4.
33. A homodimer consisting of two non-covalently associated fusion products as claimed in claim 22.
34. A DNA sequence encoding the fusion product as claimed in claim 22.
35. An expression vector having the DNA sequence as claimed in claim 34 inserted therein in an operable form.
36. A host cell transformed with the expression vector as claimed in claim 35.
37. A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.
38. A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.
39. A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33.
40. A process for preparing a fusion product as claimed in claim 22 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.
41. A process for preparing a recombinant Fel d 1 polypeptide comprising the steps of synthesising the fusion product as claimed in claims 26 or 27 and selectively cleaving the linker.
Description:
[0001]This invention relates to a recombinant allergen and in particular
to a recombinant Fel d 1, the major cat allergen, which is functionally
equivalent to the natural allergen.
[0002]Exposure to airborne particles derived from household cats (Felis domesticus) is a common cause of IgE-mediated allergy in, for example, Europe and the US (see Ichikawa, K., et al. (1999) Clin Exp Allergy 29, 754-761; Roost, H. P., et al. (1999) J Allergy Clin Immunol 104, 941-947 and Lau, S., et al. (2000) Lancet 356, 1392-1397). Indeed, cats are found in about 25% of households in Western countries and allergy to cats is found in a large part of the population, e.g. about 10% in the US. The severity of symptoms range from relatively mild rhinitis and conjunctivitis to potentially life-threatening asthmatic exacerbation.
[0003]Treatment of cat allergy by allergen injections is often employed but clinical results are variable since for cat allergy, only crude dander extract is available for treatment (see Lilja, G., et al. (1989) J Allergy Clin Immunol 83, 37-44 and Hedlin, G., et al. (1991) J Allergy Clin Immunol 87, 95.5-964) although alternative formulations have been proposed (see Norman, P. S., et al. (1996) Am J Respir Crit Care Med 154, 1623-1628 and Oldfield, W. L., et al. (2002) Lancet 360, 47-53).
[0004]Although patients are occasionally sensitised to several different molecules in cat dander and pelts, e.g. albumin and cystatin, the major allergen is Fel d 1 (i.e. Felis domesticus allergen 1, formerly termed Cat 1). The importance of this allergen has been emphasised in numerous studies. In fact more than 80% of cat allergic patients exhibit IgE antibodies to this potent allergen (see Ohman, J. L., Jr., et al. (1977) J Allergy Clin Immunol 60, 317-323 and van Ree, R., et al. (1999) J Allergy Clin Immunol 104, 1223-1230).
[0005]Fel d 1, was first described 25 years ago as the dominant cat allergen and several subsequent studies have characterised the biochemical and immunological nature of Fel d 1 (see Ohman, J. L., Jr., et al. (1974) J Immunol 113, 1668-1677; Leitermann, K., et al. (1984) J Allergy Clin Immunol 74, 147-153; Chapman, M. D., et al. (1988) J Immunol 140, 812-818; Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309; Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694; van't Hof, W., et al. (1993) Allergy 48, 255-263; van Milligen, F. J et al. (1994) J Allergy Clin Immunol 93, 34-43; Vailes, L. D., et al. (1994) J Allergy Clin Immunol 93, 22-33; Counsell, C. M., et al. (1996) J Allergy Clin Immunol 98, 884-894; Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908 and Batard, T., et al. (2000) J Allergy Clin Immunol 106, 669-676).
[0006]The allergen is a 35-39 kDa acidic glycoprotein containing 10-20% N-linked carbohydrates and is found in the pelt, saliva and lachrymal glands of cats. It is formed by two non-covalently linked heterodimers, each consisting of one 70 residue peptide (known as "chain 1") and one 85, 90 or 92 residue peptide (known as "chain 2") encoded by separate genes (see Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309; Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908; Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694 and Griffith, I. J., et al. (1992) Gene 113, 263-268). (Chain 1 shares limited (30%) sequence homology with rabbit uteroglobulin/human Clara cell 10 kDa protein (CC10) and the mature natural (n)Fel d 1 has been associated with gelatin and fibronectin degrading activity.)
[0007]Several variants of Fel d 1 have been observed and are reported in the references cited hereinabove. The primary structure of chain 1 is the sequence of SEQ ID NO 1. Reported variants of chain 1 are Lys29→Arg or Asn and Val33→Ser. The primary structure of chain 2 is the sequence of SEQ ID NO 2 or 3. Reported variants of chain 2 are Asn19→Ser, Gly20→Leu, Ile55→Val, Arg57→Lys, Val58→Phe, Glu69→Val, Tyr72→Asp, Gln79→Glu and Asn88→Lys (see Kristensen, A. K, et al. (1997) Biol Chem 378, 899-908).
[0008]Furthermore, three inter-chain disulfide bridges linking the two peptides in native Fel d 1 have been identified, i.e. 3Cys(1)-73Cys(2), 44Cys(1)-48Cys(2) and 70Cys(1)-7Cys(2), suggesting an anti-parallel orientation of Fel d 1 peptides. See Kristensen, A. K., et al. (1997) Biol Chem 378, 899-908.
[0009]Several attempts have been made to associate the separate peptides into a native-like allergen in E coli with only partial success (see Bond, J. F., et al. (1993) Mol Immunol 30, 1529-1541; Keating, K. M., et al. (1995) Mol Immunol 32, 287-293 and Slunt, J. B., et al. (1995) J Allergy Clin Immunol 95, 1221-1228) and recently a soluble and immunoreactive chain 1-linker-chain 2-fusion expressed in baculovirus has been described in which the linker is a peptide having 19 amino acid residues.
[0010]A mix of the separate chains has proven to be useful for in vitro allergy diagnosis, but so far no soluble, stable and correctly folded recombinant (r)Fel d 1 homodimer with retained disulfide formation has been available (see van Ree, R., et al. (1999) J Allergy Clin Immunol 104, 1223-1230 and Slunt, J. B., et al. (1995) J Allergy Clin Immunol 95, 1221-1228).
[0011]Accordingly, the present invention provides a recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2 and a linker selected from a carbon-nitrogen bond or a short-peptide linker which links the N-terminal amino, acid of one chain to the C-terminal amino acid of the other chain.
[0012]The present invention will now be described with reference to the following drawings, in which
[0013]FIG. 1 shows the primary structure and disulfide bridges of the recombinant His-tagged rFel d 1(2+1) fusion molecule;
[0014]FIG. 2 shows the results of size exclusion chromatography of rFel d 1(2+1);
[0015]FIG. 3 shows the deconvoluted electrospray mass spectrum from analysis of rFel d 1(2+1);
[0016]FIG. 4 shows the electrospray mass spectrum from analysis of non-reduced rFel d 1(2+1) digested with trypsin;
[0017]FIG. 5 shows the time-dependent dissociation analysis of immobilised rFel d 1(2+1) by surface plasmon resonance;
[0018]FIG. 6 shows the result of a far-UV CD analysis of rFel d 1 and nFel d 1;
[0019]FIG. 7 shows the IgE responses to Fel d 1 in individuals sensitised to cats in direct ELISA;
[0020]FIG. 8 shows the dose-dependent inhibition of serum IgE from a pool of individuals sensitised to cats; and
[0021]FIG. 9 shows the biologic activity of rFel d 1(2+1) and nFel d 1 in two patients allergic to cats.
[0022]The present invention demonstrates that a protein derived from a fusion of the genes coding for the two polypeptide chains constituting Fel d 1 can be folded to resemble closely the structure and allergenic activity of natural (n)Fel d 1. Surprisingly, it has been found that such a recombinant protein mimics the structure and allergenic activity of nFel d 1 when the two peptide chains are linked by a carbon-nitrogen bond or a short peptide linker. Synthetic genes coding for the two Fel d 1 chains may be produced using known techniques, for example by PCR by overlapping oligonucleotides and expression as refolded His-tagged proteins in E coli. Two possible constructs, namely one with chain 1 and the other with chain 2 in the N-terminal position, are exemplified. Both constructs have been purified to homogeneity and analysed, in particular for intra-molecular disulfide bridges and homodimer formation using techniques such as size exclusion chromatography, mass spectrometry and surface plasmon resonance.
[0023]As explained hereinabove, the two polypeptide chains constituting nFel d 1 are known and described extensively in the prior art. The sequence of chain 1 of nFel d 1 is as shown in SEQ ID NO 1 and the sequence of chain 2 is as shown in SEQ ID NO 2 or 3. However, as well as the variants described hereinabove, any homologous peptide or peptide fragment which has substantially the same sequence and/or provides substantially the same function in the rFel d 1 as chain 1 or chain 2 of nFel d 1 may be used in the present invention. The homologues or fragments of chain 1 or chain 2 must provide substantially the same allergenic activity in the rFel d 1 of the present invention as in nFel d 1. Allergenic activity may be measured by any of the known techniques in the art, such as the response to IgE. Preferably no significant difference in response to IgE between the recombinant and natural Fel d 1 is observed. Preferably the homologues should also provide for the adoption of substantially the same conformation as in nFel d 1.
[0024]The linker which links chain 1 and chain 2 is a key feature of the present invention. Although attempts have been made to provide a rFel d 1 using chains 1 and 2 from nFel d 1 with a linker, such efforts have been unsuccessful. The present applicant has found, however, that rFel d 1 which mimics the properties of nFel d 1 may be obtained by linking chain 1 and chain 2 with a linker selected from a carbon-nitrogen bond and a short peptide, i.e. having from 1 to 9, preferably 1 to 5, particularly preferably 1 to 3 amino acids.
[0025]Surprisingly, a bond or a short peptide does not induce significant constraints or unfolding, as shown by comparison with nFel d 1 in circular dichroism (CD) measurements.
[0026]Preferably the linker is a carbon-nitrogen bond thereby providing a direct fusion between chain 1 and chain 2. An advantage of direct fusion is that no extra amino acids are included within the molecule which otherwise might compromise the use of the molecule in diagnosis and treatment. However, a short (1 to 9 amino acids) peptide bond may be tolerated. An advantage of including a short peptide chain is that the linker may then be used as a target site for a reagent, such as an enzyme, capable of selectively cleaving the polypeptide at the linker. By selective, the applicant means that the polypeptide is cleaved at the linker rather than within chain 1 or chain 2. Such a cleavage would then provide a rFel d 1 having substantially the same structure as nFel d 1, i.e. in which chain 1 and chain 2 are covalently bonded together only by the disulfide bridges.
[0027]The present invention therefore also provides a process for preparing a recombinant Fel d 1 peptide comprising the steps of synthesising the peptide having the linker as described herein and selectively cleaving the polypeptide at the linker, using a suitable reagent and preferably an enzyme. Such reagents and enzymes are well known in the art.
[0028]The linker links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain. Preferably the linker links the N-terminal amino acid of chain 1 to the C-terminal amino acid of chain 2 providing a so-called (2+1) construct. Thus, rFel d 1(1+2) contains chain 1 and chain 2 in which the C-terminal of chain 1 is fused to the N-terminal of chain 2 and rFel d 1(2+1) contains chain 1 and chain 2 in which the N-terminal of chain 1 is fused to the C-terminal of chain 2 as shown in FIG. 1 and SEQ ID NO 4. Both chains show specific IgE reactivity although results suggest that rFel d 1(2+1) exhibits superior IgE reactivity to rFel d 1(1+2).
[0029]As well as the linker described hereinabove, chains 1 and 2 of the rFel d 1 of the present invention will also be linked by one or more disulfide bridges on account of the presence of cysteine residues in each chain. Biological recognition of proteins is dependent on the primary structures, displayed as linear T cell epitopes in the cavity of MHC molecules on antigen presenting cells. Equally important for the biological functions are the three-dimensional structures, which in turn depends on secondary structure and frequently on correct and stable disulfide bridges. The rFel d 1 should have at least one disulfide bridge and preferably 2 or 3, particularly preferably 3, as in nFel d 1. The applicant has analysed rFel d 1(2+1) by CD measurements and determined the intra-chain disulfide linking through trypsin cleavage and mass spectrometry. The secondary structure and disulfide bridges pattern of nFel d 1 as well as the proliferation of cultured PBMC in the presence of nFel d 1 were found to correspond well to those observed for rFel d 1(2+1). Thus, the rFel d 1 forms a basis for a stable and immunoreactive allergen
[0030]An important structural feature of nFel d 1 is the formation of stable non-covalently associated homodimers. The ability of rFel d 1(2+1) to form homodimers has been investigated by several methods, including CD spectroscopy and analysis of IgE antibody responses in direct and competition ELISA using sera from individuals sensitised to cat was carried out. The biological activity was demonstrated by the induction of CD203c on basophils of cat allergic patients.
[0031]The 30 kDa rFel d 1(2+1) fraction isolated by size exclusion chromatography (SEC) indicates a homodimer by virtue of its elution position and corresponding molecular weight. The difference in molecular weight to the cat dander derived 35-38 kDa nFel d 1 may be explained by the presence of 10-20% N-linked carbohydrates in the natural allergen. The applicant further investigated the possible homodimer formation via re-chromatography of the isolated 30 kDa fraction by SEC under dissociating conditions. Now the corresponding component eluted as a 15 kDa peak in agreement with the findings from SDS-PAGE using non-reduced sample, suggesting a non-covalently associated dimer. Finally, the rFel d 1(2+1) was analysed by surface plasmon resonance with the assumption that a dissociation rate should be possible to calculate if a dimer was attached to the chip. The time-dependent dissociation indicated a tight protein-protein association which was also supported by the fact that no peak corresponding to the size of a monomer could be detected in SEC. Furthermore, the sensorgram obtained suggested a dimer by the roughly 50% decrease in response measured after deactivation.
[0032]From a clinical perspective, as well as for epitope probing, it is important to establish accurate levels of allergen-specific antibodies in serum from e.g. cat-allergic patients. The ability to detect allergen specific IgE in serum from 15 cat-allergic patients to rFel d 1(2+1), nFel d 1 and a mixture of Fel d 1 peptides, was evaluated using direct ELISA. No significant difference in response to IgE was detected for recombinant and natural Fel d 1 indicating that all relevant IgE epitopes are present in the rFel d 1(2+1) structure. Also, the results confirm that the carbohydrate side-chain is not crucial for the folding or else serves as an epitope of nFel d 1. The comparable behaviour of rFel d 1 and nFel d 1 was also implied in the competition ELISA.
[0033]rFel d 1 and nFel d 1 revealed the same capacity to compete with IgE in serum for binding to microtitre plate bound nFel d 1 in ELISA. The somewhat better homologous inhibition achieved using high concentrations of nFel d 1 is likely to be caused by the inhibition of antibodies present in the serum pool by matching impurities in the nFel d 1 preparation. A mixture of chains 1 and 2 (with no linker) showed significantly lower IgE binding capacity in direct ELISA and a lower specific activity in the inhibition assay, suggesting a distorted protein preparation with fewer exposed epitopes.
[0034]The present invention also provides a DNA sequence encoding the rFel d 1 described herein as well as an expression vector capable of expressing the DNA sequence in an operable form. Although exemplified by E. coli, the skilled person would be aware that other known cell lines would be capable of preparing rFel d 1. Accordingly the present invention also provides a host cell transformed with the expression vector as described above. A high level expression E coli system which produces proteins without the attached carbohydrates has been exemplified herein. However, other known systems may be used which provide for the attached carbohydrates and fall within the scope of the present invention.
[0035]rFel d 1 of the present invention may be used for diagnosis and therapy of cat-allergic patients. Specifically the present invention provides a pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product and/or the homodimer as described herein. The present invention also provides for the use of the fusion product and/or the homodimer as described herein for the preparation of a medicament for the treatment or prevention of cat allergy as well as a method for treating cat allergy, using the fusion product and/or the homodimer as described herein.
[0036]The present invention also provides a kit for the diagnosis of a cat allergy comprising the fusion product and/or the homodimer as described herein as well as a method for the diagnosis of an cat allergy comprising obtaining a sample from a subject and combining with the sample the fusion product and/or the homodimer as described herein.
[0037]Although the subject treated or diagnosed is preferably a human subject, the subject may be any non-human mammal, such a dog.
EXAMPLES
Example 1
Natural and Recombinant Fel d 1
[0038]Standard (see Ausubel, F. A., et al. (eds) (1998) Current Protocols in Molecular Biology, John Wiley & Sons, New York) or manufacturers' protocols were used for DNA manipulations. From published amino acid sequences of Fel d 1 chain 1 and 2 (see Chapman, M. D., et al. (1988) J Immunol 140, 812-818; Duffort, O. A., et al. (1991) Mol Immunol 28, 301-309 and Morgenstern, J. P., et al. (1991) Proc Natl Acad Sci USA 88, 9690-9694) synthetic genes were made by PCR-amplification (Eppendorf Mastercycler, Hamburg, Germany) using overlapping DNA-primers from DNA Technology A/S (Århus, Denmark) as shown in Table 1 and which are designated as SEQ ID NOS 5-15. In Table 1, restriction enzyme sites (Nde I and Xho I) are underlined. Forward (F) and reverse (R) primers are indicated.
TABLE-US-00001 TABLE 1 Primer no. Sequence 1(F) 5'-gtacatatg g aaatctgccc ggctgttaaa cgtgacgttg acctgttcct gaccggtacc ccggacgaat acgttgaaca ggttg-3' 2(R) 5'-ggcagagctt tgtactgagc aacctgttca acgtattcgt ccgggtgagc aacctgttca acgtattc-3' 3(F) 5'-tgctcagtac aaagctctgc cggttgttct ggaaaacgct cgtatcctga aaaactgcgt tgacgctaaa atgacc-3' 4(R) 5'-cctctcgag g cacagcgggg aggtgtagat tttgtccagc agggacagag cgttttcttt gtcttcttcg gtcattttag cgtcaacgc-3' 5(F) 5'-gtacatatg g ttaaaatggc tgaaacctgc ccgatcttct acgacgtttt cttcgctgtt gctaacggta acgaac-3' 6(R) 5'-ggtacgttcc ggttcggtag cgttaacttt ggtcagggac aggtccagca gcagttcgtt accgttagca acagc-3' 7(F) 5'-ctaccgaacc ggaacgtacc gctatgaaaa aaatccagga ctgctacgtt gaaaacggtc tgatctcccg tgttctggac-3' 8(R) 5'-gcttcaccca tgcagtcttt ggaggaggag atggtggtca taaccagacc gtccagaaca cgggagatca g-3' 9(F) 5'-caaagactgc atgggtgaag ctgttcagaa caccgttgaa gacctgaaac tgaacaccct gggtcgctcg agagg-3' 10(R) 5'-cctctcgag a cgacccaggg tg-3' 11(linker) 5'-cgtttaacag ccgggcagat ttcacgaccc agggtgttca gtttc-3'
[0039]PCR-reactions (10 μl) containing 1 pmol of each primer, 1-4 for chain 1 and 5-10 for chain 2, using AmpliTaq DNA polymerase (Applied Biosystems, Foster City, Calif., USA) was used. The reactions proceeded for 1.0 min at 94° C., 1.5 min at 65° C. and 2.0 min at 68° C. for 30 cycles. The PCR products were ligated into pT7Blue Blunt Vector, transformed into Nova Blue Single Competent cells using Perfectly Blunt Cloning Kit Novagen Inc., Madison, Wis., USA). Single colonies were grown in 2.5 ml LB medium containing 100 μg/ml ampicillin and plasmids were purified (Qiagen, GmbH, Hilden, Germany) and cut with the restriction enzymes Nde I and Xho I followed by electrophoretic analysis in 0.3 μg/ml ethidium bromide in 1% agarose gels. Clones with the right size insert (210 and 276 bp for chain 1 and 2, respectively) were sequenced (ABI PRISM® 377 DNA Sequencer, Applied Biosystems). Verified plasmids were used as templates to join chains 2 and 1, using primers 4, 5 and 11 as described for the single chains. After sequencing, the fusion constructs were subcloned into pET 20b (Novagen) using the Nde I/Xho I restriction sites and transformed into E coli strain BL-21(DE3)pLysS (Novagen). Clones were selected on LB agar plates with ampicillin (100 mg/l) and chloramphenicol (30 mg/l) and grown in LB medium containing 100 μg/ml ampicillin and 30 μg/ml chloramphenicol. pET 20b inserts of chain 1, chain 2 and rFel d 1(2+1) were sequence verified, (ABI). Expression of protein was induced for 3 h in midlog-phase using 0.4 mM isopropyl-thiogalactoside. The cells were pelleted using a J2-21 centrifuge (Beckman Instruments Inc., Palo Alto, Calif., USA) at 1000×g for 10 min and stored at -20° C. Natural Fel d 1 (>90% pure) from Indoor Biotechnologies (Charlottesville, Va., USA) was used for comparison of immunoreactivity and biological activity between samples.
Example 2
Purification and Characterisation of Recombinant Fel d 1
[0040]Protein purification was performed using FPLC, (Amersham Biosciences, Uppsala, Sweden). The same purification protocol was used for all recombinant constructs. The E coli pellets containing the expressed recombinant construct were resuspended in 20 mM Tris/HCl, 0.2 M NaCl, 1 mM EDTA, pH 7.4, and disrupted via 8×10 seconds sonication bursts on ice (Soniprep 150 Ultrasonic Disintegrator, Sanyo Gallenkamp, Uxbridge, UK) followed by centrifugation at 12000×g for 25 min (Beckman Instruments). This procedure was repeated twice, after which the pelleted inclusion body preparation was solubilised in 6 M guanidine/HCl, 20 mM Tris/HCl, 0.5 M NaCl, 5 mM imidazole, pH 8.0, and loaded onto a 5 ml Ni+-HiTrap affinity column (Amersham Biosciences) operated at 5 ml/min. The column buffer was changed to 6 M urea, 20 mM Tris/HCl, 0.5 M NaCl, 20 mM imidazole, pH 8.0, and a linear gradient was formed to reach 20 mM Tris/HCl, 0.5 M NaCl 20 mM imidazole, pH 8.0, after 12 column volumes. The protein was eluted with 20 mM Tris/HCl, 0.5 M NaCl, 0.5 M imidazole, pH 8.0. The enriched rFel d 1 preparation was purified by size exclusion chromatography (SEC) (HiLoad® 16/60 Superdex 200 pg, Amersham Biosciences) equilibrated in PBS and in PBS with 0.1% SDS at 1 ml/min. Molecular weight calibration of the column was carried out using bovine serum albumin (BSA), 67 kDa; ovalbumin, 43 kDa; chymotrypsinogen A, 25 kDa and ribonuclease A, 13.7 kDa (Amersham Biosciences) dissolved in PBS or PBS with 0-1% SDS. The relative elution of reference proteins and rFel d 1(2+1) was calculated according to the formula Kav=Ve-VoNt-Vo (see Scopes, R. K. (1994) Protein Purification, Principles and Practice, 3rd ed. Ed (Cantor, C. R., Ed.), Springer-Verlag, New York, USA). Purified proteins were stored at -80° C. until use.
[0041]The protein concentration of rFel d 1(2+1) was analysed by amino acid analysis using a Biochrom 20 Plus ninhydrin-based analyser (Amersham Biosciences) after hydrolysis at 110° C. for 24 h in evacuated tubes with 6 M HCl containing 0.5% (w/v) phenol. The BCA protein assay (Pierce, Rockford, Ill., USA) was sometimes used to estimate the protein concentration. Purity was judged by SDS-PAGE using 15% homogeneous gels and low molecular weight markers (Amersham Biosciences). Samples were denatured at 98° C. for 5 min in SDS sample buffer with or without β-mercaptoethanol (see Ausubel, F. A., et al. (eds). (1998) Current Protocols in Molecular Biology, John Wiley & Sons, New York).
Example 3
Electrospray Mass Spectrometry and Determination of Disulfide Bridges
[0042]For mass determination of rFel d 1(2+1), the folded protein was dissolved at 27 pmol/μl in 10 mM ammonium acetate (pH 7.3) and was applied to electrospray ionisation (ESI) mass spectrometry (below) via direct infusion using a syringe pump at 2-5 μl/min (Harvard Apparatus, Holliston, Mass., USA).
[0043]To localise disulfide bridges, 2.7 mmol of the folded rFel d 1(2+1) was dissolved in 10 μl 9 M urea and incubated 30 min under vortex at 45° C. after which 10 μl water was added. Modified trypsin (5 μg, Promega) and 10 μl 0.5 M ammonium bicarbonate (pH 8.0) were added followed by water to yield a final volume of 100 μl. Digestion proceeded overnight under vortex at 37° C. The reaction was quenched by adding 1 μl neat trifluoroacetic acid to the sample which was stored at -20° C. until analysed. Before mass spectrometry, aliquots of the tryptic digest (10 μl) were desalted on μ-C18 ZipTips (Millipore, Bedford, Mass.; USA) and eluted in 60% acetonitrile containing 1% acetic acid for nano-ESI mass spectrometry. To make sure that no free sulfhydryl groups existed in rFel d 1(2+1), alkylation was carried out on the non-reduced recombinant preparation (5.4 nmol) using iodoacetamide (Sigma, St. Louis, Mo., USA) at 5.5 mM in 20 mM ammonium bicarbonate (pH 8.0) for 15 min at room temperature followed by desalting on μ-C4 ZipTips and nano-ESI mass spectrometry.
[0044]Mass spectra were recorded using a quadrupole time-of-flight tandem mass spectrometer, Q-TOF (Micromass, Altrincham, UK). The instrument was equipped with an orthogonal sampling ESI-interface (Z-spray, Micromass). Metal-coated nano-ESI needles (Protana, Odense, Denmark) were used and manually opened on the stage of a light microscope to give a spraying orifice of about 5 μm. This resulted in a flow of approximately 20-50 nL/min when a capillary voltage of 0.8-1.2 kV was applied. A nitrogen counter-current drying gas facilitated desolvation. The cone voltage was set at 40 V.
[0045]The amino acid sequence and the disulfide bridges as determined by nano-ESI mass spectrometry after tryptic digestion of the E coli expressed (His)6-tagged rFel d 1(2+1) fusion protein is shown in FIG. 1 and SEQ ID NO 4. Following column folding and purification by Ni+-chelate chromatography, dominant fractions in SEC with apparent molecular weights of 30 kDa and 51 kDa (FIG. 2) were recovered for further analysis. The 51 kDa component contained inter-chain S--S bonds as shown by a 35 kDa band in non-reducing and a 20 kDa band in reducing SDS-PAGE and was not further analysed (FIG. 2). The 30 kDa fraction which showed a single 30 kDa peak upon re-chromatography, exhibited 16 and 20 kDa bands by non-reducing and reducing SDS-PAGE respectively, (FIG. 2). When subjected to electrospray mass spectrometry, rFel d 1(2+1) revealed a molecular mass of 19177 Da, which corresponds to the average molecular mass (19183 Da) minus 6 Da, indicating the existence of three disulfide bridges in the structure (FIG. 3). Also seen is an additional peak at 19046 Da, which corresponds to the full-length rFel d 1 without the initiating methionine (Table 1, and residue 0 in FIG. 1 and SEQ ID NO 4). The purity of both the natural and recombinant preparations were >95% as judged by SDS-PAGE (data not shown).
[0046]The disulfide bridge formation in rFel d 1(2+1) was analysed by nano-ESI mass spectrometry after trypsin digestion of the non-reduced preparation and the results are shown in Table 2 and FIG. 4.
TABLE-US-00002 TABLE 2 Theoretial Experimental Tryptic mass mass fragment Residues Sequence [M + H] [M + H] T5 44-44 (K)K(I) 147.11 not found TI1 100-100 (K)R(D) 175.12 not found T14 132-134 (R)ILK(N) 373.28 not found TI 0-2 (-)MVK(M) 377.22 not found T4 40-43 (R)TAMK(K) 450.24 450.75 T9 87-92 (K)LNTLGR(E) 673.40 673.40 T16 141-146 (K)MTEEDK(E) 752.31 not founda T3 32-39 (K)VNATEPER(T) 915.45 915.44 T17 147-155 (K)ENALSLLDK(I) 1002.55 not founda T13 122-131 (K)ALPVVLENAR(I) 1081.64 1081/60 T7 58-71 (R)VLDGLVMTTISSSK(D) 1450.78 1450.72 T6 45-57 (K)IQDCYVENGLISR(V) 2156.01 2155.98 T15 135-140 (K)NCVDAK(M) T8 72-86 (K)DCMGEAVQNTVEDLK(L) 2408.11 2408.07 T10 93-99 (R)EICPAVK(R) T12 101-121 (R)DVDLFLTGTPDEYYEQVAQYK(A) 2430.17 2430.09 T2 3-31 (K)MAETCPIFYDVFFAVANGNELLLDLSLTK(V) 5092.46 5092.28 T18 156-170 (K)IYTSPLCLEHHHHHH(-) T16 + 17 141-155 (K)MTEEDKENALSLLDK(I) 1735.86 1735.80 a Not found as a separate fragment. Detected as a part of the larger fragment T16 + T17 with [M + H] 1735.80, resulting from a miscleavage at Lys146 which is surrounded by acidic residues, see FIG. 1.
Example 4
Homodimer Dissociation Constant Analysis
[0047]A BIACORE® 2000 instrument (Biacore AB, Uppsala, Sweden) was employed to investigate homodimer formation of rFel d 1(2+1) by evaluation of the decrease in response relative to maximum binding to the chip surface and the associated dissociation constant. rFel d 1(2+1) and for control purpose a monomer protein, BB (see Batard, T., et al. (2000) J Allergy Clin Immunol 106, 669-676), were immobilised onto the surface of CM-5 chips (research grade) via amine coupling to a carboxylated dextran layer using N-hydroxysuccinimide/N-ethyl-N'-(3-diethylaminopropyl)carbodiimide (NHS/EDC) chemistry according to the manufacturers recommendations. The time intervals between surface activation (240-660 s, 35 μl), protein immobilisation (900-1140 s, 20 μl) dissociation phase (1140-1940 s, 67 μl) and surface deactivation (1940-2060 s, 10 μl) were kept constant. In the immobilisation step, 20 μl of a protein solution containing 0.05 μg/μl in 10 mM sodium acetate (pH 4.5) was injected over the NHS/EDC activated surface. After the dissociation phase, the surface was deactivated by injection of 10 μl ethanolamine. The decrease in percent of protein initially attached to the chip surface was calculated as follows: [Response Units (RU) after protein immobilisation at 1230 s--RU after deactivation/RU after protein immobilisation]×100. All experiments were performed at 25° C. and 5 μl/min. The running buffer was 10 mM Hepes (pH 7.4), 0.15 M NaCl, 3.4 mM EDTA, 0.05% surfactant P20. The dissociation constant analysed at 1230-1235 s was based on the equilibrium responses and calculated using the 3.0 software.
[0048]The 30-40 kDa molecular size detected for rFel d 1(2+1) suggests a non-covalent dimerisation similar to that exhibited by natural Fel d 1. This was investigated by BIACORE® analysis and by SEC under dissociating elution conditions. In the latter case, the 30 kDa rFel d 1(2+1) fraction produced a single peak corresponding to a molecular weight of 15 kDa using PBS with 0.1% SDS in the running buffer (data not shown). The 30 kDa fraction was further analysed by surface plasmon resonance with the assumption that dissociation of the two subunits can be recorded. As a control, monomeric protein, BB (39), was used, (FIG. 5). The rFel d 1(2+1) construct and the BB monomer bound to the sensor chip in a similar manner. The time-dependent decrease in RU after immobilisation of the rFel d 1(2+1) molecule to the chip surface was 53%. In contrast, the BB monomer exhibited a stable association to the chip surface during the same time period. In addition, the dissociation constant was determined shortly after the immobilisation phase to be 8.74 10-4 s-1.
Example 5
CD Measurements
[0049]CD measurements of the natural and recombinant Fel d 1 were performed in MilliQ water with protein concentrations of 1.56×10-5 M (here determined using Bio-Rad Protein Assay, Bio-Rad Laboratories, Vienna, Austria). The investigations were carried out on a Jasco J-715 spectropolarimeter (JASCO Labor-und Datentechnik GmbH, Gross-Umstadt, Germany) using a 0.1 cm pathlength cell equilibrated at 20° C. Spectra were recorded with 0.5 nm resolution at a scan speed of 100 nm/min and resulted from averaging 3 scans. The final spectra were baseline-corrected by subtracting the corresponding MilliQ spectra obtained under identical conditions. Results were expressed as the molar mean residue ellipticity [Θ] at a given wavelength. The data were fitted with the secondary structure estimation programs Dicroprot (37) and J-700 (JASCO) using miscellaneous data deconvolution algorithms.
[0050]The 20° C. CD spectra of natural and recombinant Fel d 1 are nearly identical, characterised by two minima at 208 nm and 222 nm and a characteristic maximum at about 195 nm (FIG. 6). The shape of the spectrum is indicative for a well folded protein with a significant α-helical secondary structure content. The secondary structure estimation resulting from the fitting procedures yields 35-40% α-helix and 7-16% β-sheet structures with root mean square deviations (CD.sub.calc-CD.sub.exp) in the range 4-11%.
Example 6
ELISA Analysis
[0051]Serum specimens from 15 individuals were selected on the basis of positive IgE responses to cat dander (range 0.45-38 kUA/L using Pharmacia Diagnostics CAP System, Uppsala, Sweden). For control purpose, a pool of 20 non-cat-allergic patients was used. The serum samples were analysed in duplicates by ELISA for IgE antibody binding to rFel d 1(2+1), nFel d 1 or a mix of rFel d 1 chain 1 and chain 2. The assay was performed as a sequential, solid phase adsorption of allergens, serum sample, primary antibody, antibody conjugate and finally substrate including rinsing four times with 250 μl PBS containing 0.05% Tween 20 (PBS-T) between incubations. If nothing else is stated, all steps were performed at room temperature. Micro titre plates (96 wells, Nunc, Roskilde, Denmark) were coated with 100 μl of rFel d 1(2+1) solution and for comparison also nFel d 1 and an equimolar mixture of chains 1 and 2, to final concentrations of 5 μg/ml in 0.1 M carbonate buffer, pH 9.6. After over-night adsorption at +4° C., the plates were emptied and the remaining protein binding sites were blocked with 200 μl PBS-T containing 1% BSA for 2.5 h at room temperature (20-22° C.). Each serum sample (100 μl) was diluted 1:1 in PBS (duplicates) and incubated for 2 h at room temperature, after which 100 μl rabbit anti-human IgE (Miab, Uppsala, Sweden, diluted 1:2000 (v/v)) was added and incubation was continued for 2 h. Finally, 100 μl goat anti-rabbit, (Dako, Denmark, diluted 1:2000 (v/v)) conjugated to alkaline phosphatase was added and incubation continued for 1 h. Alkaline phosphatase substrate tablets (Sigma 104® Diagnostics, St Louis, Mo., USA) were used and the color reaction monitored at 405 nm was registered in an automated ELISA reader (Multiskan RC, Labsystems, Helsinki, Finland). Competition assay of serum IgE was performed using pooled sera from individuals sensitised to cat with more than 10 kUA/L response to cat dander (mean concentration, 23 kUs/L), (Pharmacia Diagnostics CAP System). Micro-titre plates (96 wells) were coated with 100 μl, 5 μg/ml nFel d 1. Three-fold serial dilutions in PBS-T of rFel d 1(2+1), nFel d 1 and an equimolar mixture of chain 1 and 2 were incubated at a 1:1 volume ratio with the serum pool diluted 1:2 (v/v) in PBS for 2 h at room temperature and thereafter added to the wells. The subsequent steps were as described for the direct ELISA.
[0052]The diagnostic relevance of a recombinant allergen lies in its ability to bind specifically IgE antibodies in body fluids or in tissues from allergic patients in a manner similar to the natural counterpart. This ability of IgE antibodies in sera from 15 subjects sensitised to cat was compared to detect rFel d 1(2+1), nFel d 1 and a Fel d 1 peptide mixture using ELISA. All sera from cat allergic patients showed elevated IgE concentrations compared to a pool of serum from non-cat allergic patients (FIG. 7). Similar responses for rFel d 1(2+1) (optical density (OD) mean, 0.412) and nFel d1 (OD mean, 0.384) were observed. There was a significantly lower IgE response to the peptide mixture (OD mean, 0.288) compared to rFel d 1(2+1) and nFel d 1, (ANOVA p<0.001 and p<0.01, respectively).
[0053]The capacity of serially diluted rFel d 1(2+1), nFel d 1 and a mixture of chain 1 and chain 2 to compete with the binding of patient IgE to microtitre plate bound nFel d 1 was compared using ELISA. All three Fel d 1 preparations exhibited competing activity. The rFel d 1(2+1) fusion protein inhibited IgE similar as nFel d 1, shown by the proximity and slopes of the dose-dependent inhibition curves in the sensitive range (0.01-0.33 μg/ml), (FIG. 8). The mixture of chain 1 and 2 exhibited more than a 25-fold reduced capacity to compete with IgE binding. By homologous inhibition of nFel d 1, a residual capacity to block IgE was evident using 1 and 3 μg/ml.
Example 7
CD203c Assay
[0054]The expression of CD203c was performed as described (see Hauswirth, A. W., et al. (2002) J Allergy Clin Immunol 110, 102-109). Briefly, heparinised blood samples were taken from two cat allergic patients. Blood aliquots (100 μl) were incubated with dilutions of recombinant and natural Fel d 1 (1 and 10 μg/ml), anti-IgE antibody (1 μg/ml) or PBS for 15 min (37° C.). After incubation, cells were washed in PBS/EDTA and then incubated with 10 μl of phycoerythrin-labeled CD203c mAb 97A6 (Immunotech, Marseille, France) for 15 min at room temperature. Thereafter, samples were subjected to erythrocyte lysis with 2 ml FACS® Lysing solution (Becton Dickinson, San Diego, Calif., USA). Cells were then washed, resuspended in PBS, and analysed by two-colour flow cytometry on a FACScan (Becton Dickinson).
[0055]The biological activity of rFel d 1(2+1) and nFel d 1 was evaluated in cell preparations donated by two cat allergic patients. The surface marker CD203c is upregulated exclusively on basophils in response to allergen cross-linking of the high affinity IgE receptor, FcεRI (38). The capacity of rFel d 1(2+1) and nFel d 1 to activate expression of CD203c on basophils was similar and compared well to that of anti-IgE, which was used as a positive control (FIG. 9a).
Example 8
Lymphoproliferation Assay
[0056]Peripheral blood mononuclear cells (PBMC) were isolated from cat-allergic patients by Ficoll (Amersham Biosciences) density gradient centrifugation. PBMC (2×105) were cultured in triplicates in 96-well Nunclone plates (Nunc) in 200 μl serum-free Ultra Culture medium (BioWhittaker, Rockland, Me.) supplemented with 2 mM L-glutamin (Sigma), 50 μM β-mercaptoethanol (Sigma) and 0.1 mg gentamicin per ml (Sigma) at 37° C. and 5% CO2 in a humidified atmosphere. Cells were stimulated with different concentrations (5, 2.5, 1.25 and 0.6 μg per well) of rFel d 1, nFel d 1 and for control purpose with recombinant birch pollen allergen Bet v 1, 4 U Interleukin-2 (IL-2) per well (Boehringer Mannheim, Germany) and medium alone. After 6 days of culture, 0.5 μCi per well [3H]thymidine (Amersham Biosciences) was added and 16 h thereafter incorporated radioactivity was measured by liquid scintillation counting using a Microbeta scintillation counter (Wallac ADL, Freiburg, Germany) and mean counts per minute (cpm) were calculated from the triplicates. The stimulation index (SI) was calculated as the quotient of the cpm obtained by antigen or interleukin-2 stimulation and the unstimulated control.
[0057]The lymphoproliferative responses after challenge of cultured PBMCs with rFel d 1(2+1) and nFel d 1 were analysed by cell incorporation of [3H]thymidine. Both rFel d 1(2+1) and nFel d 1 exhibited equally good proliferation in contrast to the major birch pollen allergen Bet v 1, which was used as a negative control (FIG. 9b). The T cell proliferation inducing growth factor IL-2 was used as a positive control.
Example 9
Statistical Analysis
[0058]Serological results using rFel d 1(2+1), nFel d 1 and the Fel d 1 peptide mixture in the direct ELISA were compared employing ANOVA repeated measures. A p-value <0.05 was considered statistically significant.
Sequence CWU
1
35170PRTFelis catus 1Glu Ile Cys Pro Ala Val Lys Arg Asp Val Asp Leu Phe
Leu Thr Gly1 5 10 15Thr
Pro Asp Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala Leu Pro 20
25 30Val Val Leu Glu Asn Ala Arg Ile
Leu Lys Asn Cys Val Asp Ala Lys 35 40
45Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys Ile
50 55 60Tyr Thr Ser Pro Leu Cys65
70292PRTFelis catus 2Val Lys Met Ala Glu Thr Cys Pro Ile Phe
Tyr Asp Val Phe Phe Ala1 5 10
15Val Ala Asn Gly Asn Glu Leu Leu Leu Asp Leu Ser Leu Thr Lys Val
20 25 30Asn Ala Thr Glu Pro Glu
Arg Thr Ala Met Lys Lys Ile Gln Asp Cys 35 40
45Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu
Val Met 50 55 60Thr Thr Ile Ser Ser
Ser Lys Asp Cys Met Gly Glu Ala Val Gln Asn65 70
75 80Thr Val Glu Asp Leu Lys Leu Asn Thr Leu
Gly Arg 85 90390PRTFelis catus 3Val Lys
Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe Ala1 5
10 15Val Ala Asn Gly Asn Glu Leu Leu
Leu Asp Leu Ser Leu Thr Lys Val 20 25
30Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Gln Asp
Cys 35 40 45Tyr Val Glu Asn Gly
Leu Ile Ser Arg Val Leu Asp Gly Leu Val Met 50 55
60Ile Ala Ile Asn Glu Tyr Cys Met Gly Glu Ala Val Gln Asn
Thr Val65 70 75 80Glu
Asp Leu Lys Leu Asn Thr Leu Gly Arg 85
904172PRTFelis catus 4Met Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp
Val Phe Phe1 5 10 15Ala
Val Ala Asn Gly Asn Glu Leu Leu Leu Asp Leu Ser Leu Thr Lys 20
25 30Val Asn Ala Thr Glu Pro Glu Arg
Thr Ala Met Lys Lys Ile Gln Asp 35 40
45Cys Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val
50 55 60Met Thr Thr Ile Ser Ser Ser Lys
Asp Cys Met Gly Glu Ala Val Gln65 70 75
80Asn Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg
Glu Ile Cys 85 90 95Pro
Ala Val Lys Arg Asp Val Asp Leu Phe Leu Thr Gly Thr Pro Asp
100 105 110Glu Tyr Val Glu Gln Val Ala
Gln Tyr Lys Ala Leu Pro Val Val Leu 115 120
125Glu Asn Ala Arg Ile Leu Lys Asn Cys Cys Val Asp Ala Lys Met
Thr 130 135 140Glu Glu Asp Lys Glu Asn
Ala Leu Ser Leu Leu Asp Lys Ile Tyr Thr145 150
155 160Ser Pro Leu Cys Leu Glu His His His His His
His 165 170585DNAArtificial
sequenceoligonucleotide primer with homology to Felis catus
5gtacatatgg aaatctgccc ggctgttaaa cgtgacgttg acctgttcct gaccggtacc
60ccggacgaat acgttgaaca ggttg
85668DNAArtificial sequenceoligonucleotide primer with homology to Felis
catus 6ggcagagctt tgtactgagc aacctgttca acgtattcgt ccgggtgagc
aacctgttca 60acgtattc
68776DNAArtificial sequenceoligonucleotide primer with
homology to Felis catus 7tgctcagtac aaagctctgc cggttgttct ggaaaacgct
cgtatcctga aaaactgcgt 60tgacgctaaa atgacc
76889DNAArtificial sequenceoligonucleotide primer
with homology to Felis catus 8cctctcgagg cacagcgggg aggtgtagat
tttgtccagc agggacagag cgttttcttt 60gtcttcttcg gtcattttag cgtcaacgc
89976DNAArtificial
sequenceoligonucleotide primer with homology to Felis catus
9gtacatatgg ttaaaatggc tgaaacctgc ccgatcttct acgacgtttt cttcgctgtt
60gctaacggta acgaac
761075DNAArtificial sequenceoligonucleotide primer with homology to Felis
catus 10ggtacgttcc ggttcggtag cgttaacttt ggtcagggac aggtccagca
gcagttcgtt 60accgttagca acagc
751180DNAArtificial sequenceoligonucleotide primer with
homology to Felis catus 11ctaccgaacc ggaacgtacc gctatgaaaa
aaatccagga ctgctacgtt gaaaacggtc 60tgatctcccg tgttctggac
801271DNAArtificial
sequenceoligonucleotide primer with homology to Felis catus
12gcttcaccca tgcagtcttt ggaggaggag atggtggtca taaccagacc gtccagaaca
60cgggagatca g
711375DNAArtificial sequenceoligonucleotide primer with homology to Felis
catus 13caaagactgc atgggtgaag ctgttcagaa caccgttgaa gacctgaaac
tgaacaccct 60gggtcgctcg agagg
751422DNAArtificial sequenceoligonucleotide primer with
homology to Felis catus 14cctctcgaga cgacccaggg tg
221545DNAArtificial sequenceoligonucleotide
primer with homology to Felis catus 15cgtttaacag ccgggcagat
ttcacgaccc agggtgttca gtttc 45163PRTArtificial
sequencepolypeptide with homology to Felis catus 16Lys Lys
Ile1173PRTArtificial sequencepolypeptide with homology to Felis catus
17Lys Arg Asp1185PRTArtificial sequencepolypeptide with homology to Felis
catus 18Arg Ile Leu Lys Asn1 5194PRTArtificial
sequencepolypeptide with homology to Felis catus 19Met Val Lys
Met1206PRTArtificial sequencepolypeptide with homology to Felis catus
20Arg Thr Ala Met Lys Lys1 5218PRTArtificial
sequencepolypeptide with homology to Felis catus 21Lys Leu Asn Thr Leu
Gly Arg Glu1 5228PRTArtificial sequencepolypeptide with
homology to Felis catus 22Lys Met Thr Glu Glu Asp Lys Glu1
52310PRTArtificial sequencepolypeptide with homology to Felis catus 23Lys
Val Asn Ala Thr Glu Pro Glu Arg Thr1 5
102411PRTArtificial sequencepolypeptide with homology to Felis catus
24Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys Ile1 5
102512PRTArtificial sequencepolypeptide with homology to Felis
catus 25Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile1 5
102616PRTArtificial sequencepolypeptide with homology to
Felis catus 26Arg Val Leu Asp Gly Leu Val Met Thr Thr Ile Ser Ser Ser Lys
Asp1 5 10
152715PRTArtificial sequencepolypeptide with homology to Felis catus
27Lys Ile Gln Asp Cys Tyr Val Glu Asn Gly Leu Ile Ser Arg Val1
5 10 15288PRTArtificial
sequencepolypeptide with homology to Felis catus 28Lys Asn Cys Val Asp
Ala Lys Met1 52917PRTArtificial sequencepolypeptide with
homology to Felis catus 29Lys Asp Cys Met Gly Glu Ala Val Gln Asn Thr Val
Glu Asp Leu Lys1 5 10
15Leu309PRTArtificial sequencepolypeptide with homology to Felis catus
30Arg Glu Ile Cys Pro Ala Val Lys Arg1 53123PRTArtificial
sequencepolypeptide with homology to Felis catus 31Arg Asp Val Asp Leu
Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu1 5
10 15Gln Val Ala Gln Tyr Lys Ala
203231PRTArtificial sequencepolypeptide with homology to Felis catus
32Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe Ala Val1
5 10 15Ala Asn Gly Asn Glu Leu
Leu Leu Asp Leu Ser Leu Thr Lys Val 20 25
303316PRTArtificial sequencepolypeptide with homology to
Felis catus 33Lys Ile Tyr Thr Ser Pro Leu Cys Leu Glu His His His His His
His1 5 10
153417PRTArtificial sequencepolypeptide with homology to Felis catus
34Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp Lys1
5 10 15Ile35171PRTFelis catus
35Met Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe1
5 10 15Ala Val Ala Asn Gly Asn
Glu Leu Leu Leu Asp Leu Ser Leu Thr Lys 20 25
30Val Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys
Ile Gln Asp 35 40 45Cys Tyr Val
Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val 50
55 60Met Thr Thr Ile Ser Ser Ser Lys Asp Cys Met Gly
Glu Ala Val Gln65 70 75
80Asn Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg Glu Ile Cys
85 90 95Pro Ala Val Lys Arg Asp
Val Asp Leu Phe Leu Thr Gly Thr Pro Asp 100
105 110Glu Tyr Val Glu Gln Val Ala Gln Tyr Lys Ala Leu
Pro Val Val Leu 115 120 125Glu Asn
Ala Arg Ile Leu Lys Asn Cys Val Asp Ala Lys Met Thr Glu 130
135 140Glu Asp Lys Glu Asn Ala Leu Ser Leu Leu Asp
Lys Ile Tyr Thr Ser145 150 155
160Pro Leu Cys Leu Glu His His His His His His 165
170
User Contributions:
Comment about this patent or add new information about this topic:
Images included with this patent application:
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
| Similar patent applications: | |
| Date | Title |
|---|---|
| 2012-03-29 | Recombinantly produced allergens |
| 2013-02-07 | Recombinant multimeric influenza proteins |
| 2010-11-18 | Recombinant rsv antigens |
| 2011-05-26 | Recombinant antigen |
| 2010-05-13 | Recombinant gelatins |
| New patent applications in this class: | |
| Date | Title |
|---|---|
| 2019-05-16 | Plif multimeric peptides and uses thereof |
| 2019-05-16 | Cancer vaccines |
| 2018-01-25 | Methods and compositions for inducing an immune response to egfrviii |
| 2018-01-25 | Peptide mixture |
| 2017-08-17 | Cancer vaccine composition |
| New patent applications from these inventors: | |
| Date | Title |
|---|---|
| 2022-07-21 | Method for the expansion of hpv immunogen specific t-cells |
| 2013-08-01 | Recombinant allergen |
| 2009-12-31 | Vaccine carrier |
| Top Inventors for class "Drug, bio-affecting and body treating compositions" | |
| Rank | Inventor's name |
|---|---|
| 1 | David M. Goldenberg |
| 2 | Hy Si Bui |
| 3 | Lowell L. Wood, Jr. |
| 4 | Roderick A. Hyde |
| 5 | Yat Sun Or |